Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Summary

A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.

Conditions

• Rosacea

Interventions

DRUG

CD07805/47 gel 0.5%

In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.

Sponsors & Collaborators

• Galderma R&D

  lead INDUSTRY

Principal Investigators

• Scott Clark, MD · Longmont Clinical PC

• Lesly Davidson, MD · Palmetto Medical Research

• Steven Davis, MD · Dermatology Clinical Research Center of San Antonio

• Michael Donahue, MD · Wilmington Medical Research

• Timothy Gardner, MD · East Tennessee Medical Research

• Michael Gold, MD · Tennessee Clinical Research Center

• Fasahat Hamzavi, MD · Hamzavi Dermatology

• Mark Lee, MD · Progressive Clinicial Research, PA

• Debra Liu, MD · Piedmont Medical Research

• Keith Loven, MD · Rivergate Dermatology Clinical Research Center, PLLC

• Michael Maloney, MD · Cherry Creek Research, Inc.

• Angela Moore, MD · Arlington Center for Dermatology

• George Murakawa, MD · Dermcenter PC - Somerset Skin Centre

• Catherine Pointon, MD · Metrolina Medical Research

• Elyse Rafal, MD · DermResearch Center of NewYork, Inc.

• Stephen Schleicher, MD · DermDox

• Joel Schlessinger, MD · Skin Specialists, PC

• Leonard Swinyer, MD · Dermatology Research Center

• Amanda Tauscher, MD · Compliant Clinical Research

• Gary Waterman, MD · Deaconess Clinic

• Jonathan Weiss, MD · Gwinnett Clinical Research Center, Inc.

• Morrissa Baskin, MD · Wenatchee Valley Medical Center, Clinical Research Department

• Steven Kempers, MD · Minnesota Clinical Study Center

• Ava Shamban, MD · The Laser Institute for Dermatology

• Harry Sharata, MD · Madison Skin & Research, Inc.

• Russell Mader, MD · TriCities Medical Research

• Girish Munavalli, MD · Dermatology, Laser & Vein Specialists of the Carolinas

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-03-31

Primary Completion

2012-06-30

Completion

2012-07-31

Countries

• United States

Study Locations